Search

Lipid metabolism, as the basis of life maintenance, is a prerequisite for cell survival, and lipid homeostasis can rapidly respond to metabolic changes in a coordinated manner. In cancers, there is an increase in lipid metabolism in cancer cells to meet the requirements for plasma membrane synthesis and energy production. Abnormal lipid metabolism plays an important role in the progression of primary liver cancer. This article reviews the association between abnormal lipid metabolism and primary liver cancer, in order to find targets for the prevention and treatment of primary liver cancer. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

In May 2023, the American Association for the Study of Liver Diseases (AASLD) published AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma (2023) online. The guidance mainly focuses on the prevention, diagnosis, and treatment of hepatocellular carcinoma (HCC) and provides corresponding suggestions and guidance for the problems existing in current clinical practice. The guidance emphasizes the importance and target population of HCC screening, specifies the diagnostic criteria and methods for early HCC, highlights the role of surgical treatment and related precautions in the treatment of HCC, and mentions the use of other treatment methods (such as radiotherapy, ablation, interventional therapy, and targeted therapy) and their own advantages and disadvantages. In addition, the guidance also introduces the details of HCC followup, such as examination items and frequency. The author’s team makes an excerpt of this guidance and systematically introduces the various key points for evaluation and related recommendations for clinical management, in order to provide a basis for the clinical management and decision- making of HCC patients from the aspect of evidence－based medicine. [ABSTRACT FROM AUTHOR]

Acute-on-chronic liver failure (ACLF) has a rapid onset, a high mortality rate, and a poor prognosis, and there is still a lack of specific pharmacotherapy and treatment methods. In recent years, an increasing number of evidence has shown that intestinal flora plays a critical role in maintaining the homeostasis of human microenvironment. Comprehensive testing of intestinal flora profile using metagenomics has demonstrated an interaction association between intestinal flora and the development and progression of chronic liver diseases. Research on the pathogenesis of ACLF has found that intestinal flora plays an important role in the pathogenesis of ACLF. Based on this, this article summarizes the changes in intestinal flora and its pathogenic mechanism in the development and progression of ACLF, so as to provide new targets for the clinical treatment of ACLF from the new perspective of intestinal flora regulation. [ABSTRACT FROM AUTHOR]

As a novel star molecule, gasdermin D (GSDMD)plays an important role in the amplification of immune inflammatory response and the process of pyroptosis. After being cleaved and activated by caspase - 1,the N - terminal of GSDMD is rapidly released, which anchors on the cell membrane and forms pores, thereby leading to pyroptosis, accompanied by the release of a large amount of the strong proinflammatory factors IL - 1ß and IL - 18. Acute / chronic liver inflammatory response and cell death are the common pathological features of liver diseases such as viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, autoimmune liver disease, liver failure, and hepatocellular carcinoma. This article summarizes the basic structural characteristics of GSDMD and elaborates on its important role in the pathological progression of various liver diseases. In addition, it is proposed that prevention and treatment strategies with GSDMD as a potential therapeutic target can provide new ideas for further studies on the clinical prevention and treatment of liver diseases. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Bile acids( BAs) are produced in the liver and are the final product of cholesterol catabolism, with a wide range of biological effects. This article reviews the research advances in the synthesis, transport, and metabolism of BAs and the role of BAs in regulating hepatocytes and immunity via enterohepatic circulation, as well as the current research on traditional Chinese medicine in the regulation of BAs, in order to further understand the mechanism of action of BAs in affecting intestinal flora and liver function, expand the knowledge of its regulatory mechanism, explore the mechanism of action of traditional Chinese medicine and related pathways in regulating BAs, and provide new ideas for the prevention and treatment of liver-related systemic diseases by regulating BAs. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the clinical effect of antiviral therapy with telbivudine antiviral therapy in parturients with hepatitis B virus (HBV) infection and a special immune status in pregnancy. Methods A retrospective analysis was performed for the clinical data of 67 HBsAg-positive chronic hepatitis B (CHB) patients with HBV DNA ＞106 IU/ml who were examined and gave birth in Beijing You′an Hospital, Capital Medical University, from January 2014 to October 2015. According to the level of alanine aminotransferase (ALT), the patients were divided into ALT ＜2×upper limit of normal (ULN) group (29 patients, group A), ALT ≥2×ULN group with antiviral therapy (20 patients, group B), and low-level ALT increase group without antiviral therapy (18 patients, group C). The patients in groups A and B were given antiviral therapy with telbivudine after 12 weeks of pregnancy. The three groups were observed in terms of the levels of HBV markers HBsAg and HBeAg, liver biochemical parameters, adverse drug reactions, and neonatal birth defects. An analysis of variance was used for comparison of continuous data between multiple groups, the chi-square test was used for comparison of categorical data between multiple groups, and the Fisher's exact test was used when the data did not meet the conditions for the chi-square test. Results There were no significant differences between the three groups in normalization rate of liver function and the change in HBsAg level at the time of delivery (both P＞0.05). The proportions of patients who achieved a ≥3 log reduction in HBV DNA level at the time of delivery were 44.8%, 85%, and 16.7%, respectively, in the three groups, and the proportions of patients who achieved a ≥50% reduction in HBeAg were 41.4%, 70.0%, and 11.1%, respectively; there were significant differences between the three groups for the two indices (χ2=19.85 and 14.74, both P＜0.001). Conclusion The right timing of antiviral therapy for pregnant women with a low-level increase in ALT can effectively reduce the risk of mother-to-child transmission. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To evaluate liver reserve function in patients with hepatitis B cirrhosis using indocyanine green (ICG) clearance test, and to investigate the correlation of ICG clearance test with Child-Turcotte-Pugh (CTP) class and the Model for End-Stage Liver Disease (MELD) score in evaluating liver function. Methods A total of 127 patients with hepatitis B cirrhosis who were hospitalized in The First Affiliated Hospital of Fujian Medical University from January 2012 to January 2015 were enrolled. ICG clearance test was performed for all the patients, and the ICG plasma clearance (K value), effective liver blood flow (EHBF), and ICG retention at 15 minutes (ICG R15) were calculated. CTP class and MELD score were also determined. An analysis of variance was used for comparison between groups, the least significant difference t-test was used for comparison between any two groups, Spearman rank correlation was performed for correlation analysis, and the area under the receiver operating characteristic (ROC) curve was used to compare liver reserve function. Results Among all the patients with hepatitis B cirrhosis, 63 had CTP class A, 45 had CTP class B, and 19 had CTP class C hepatitis B cirrhosis. With the increasing CTP class, ICG R15 gradually increased, while EHBF and K value gradually decreased (F=146.96，91.26 and 40.94，P=0.001,0.003 and 0.005). In the evaluation of liver function, ICG R15 was positively correlated with MELD score and CTP class (r=0.525 and 0.838, both P＜0.01) and was negatively correlated with EHBF and K value (r=-0.703 and -0.901, both P＜0.01). The area under the ROC curve was 0.85 for ICG R15 and 0.65 for MELD score. ConclusionI CG test can accurately and dynamically reflect liver reserve function, and ICG R15 can evaluate liver reserve function better than CTP class and MELD score. [ABSTRACT FROM AUTHOR]